预约演示
更新于：2025-07-15
Bromfenac Sodium
溴芬酸钠
更新于：2025-07-15
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-15), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H30Br2N2Na2O9 |
InChIKeyUCZFEKWQIBDZNH-UHFFFAOYSA-N |
CAS号120638-55-3 |
关联
73
项与 溴芬酸钠 相关的临床试验NCT05626478
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt in Conjunction With Topical Drop Regimen Treating Pain and inflamMation Following Cataract Surgery Compared to SOC Topical Drop Regimen
NCT06785090
Effects of Topical Bromfenac Solution on Macular Thickness in Cataract Patients Undergoing Phacoemulsification Surgery
NCT05107921
Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation
100 项与 溴芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 溴芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 溴芬酸钠 相关的专利（医药）
登录后查看更多信息
420
项与 溴芬酸钠 相关的文献（医药）2025-07-01Journal of vitreoretinal diseases
Resolution of Myopic Macular Retinoschisis and Macular Hole With Topical Medical Therapy
Article
作者: Nakahira, Shay ; Yamane, Kael ; Tom, Elysse S. ; Chen, Jasmine ; Kokame, Gregg T. ; Luo, Emi
Purpose:
To report a case of myopic macular retinoschisis and full-thickness macular hole (FTMH) that both resolved with topical medical therapy alone.
Methods:
A retrospective chart review was performed.
Results:
A patient with myopic retinoschisis with an FTMH and increased symptoms of metamorphopsia was treated with topical medical therapy consisting of 1% prednisolone, 4 times daily, and 0.07% bromfenac, daily. Anatomic changes at 6 weeks included drawing together of the inner retinal edges around the MH and its subsequent closure with marked resolution of the myopic retinoschisis.
Conclusions:
Severe myopic macular retinoschisis and an FTMH both resolved with topical therapy consisting of steroidal and nonsteroidal anti-inflammatory medications. This rapid resolution contradicts current theories of the pathogenesis of myopic macular retinoschisis.
2025-05-01Retinal cases & brief reports
NONSURGICAL CLOSURE OF FULL-THICKNESS MACULAR HOLE UNDER TOPICAL THERAPY IN TWO EYES WITH PATHOLOGIC MYOPIA
Article
作者: Aoki, Shuichiro ; Kitamoto, Kohdai ; Ueta, Takashi ; Azuma, Keiko ; Miyata, Mana ; Obata, Ryo
Background/Purpose::
Nonsurgical closure of a full-thickness macular hole (FTMH) with eye drops has recently been reported, but there are few similar reports on cases with pathologic myopia.
Methods::
Case report.
Results::
(Case 1) The right eye of a 75-year-old female patient with an axial length of 28.83 mm had undergone anti–vascular endothelial growth factor treatment for choroidal neovascularization presented with FTMH. Topical betamethasone, bromfenac, and brinzolamide treatments were started, and the FTMH was closed with visual improvement (20/32 to 20/20) after 5 weeks. (Case 2) In the right eye of a 55-year-old male patient with an axial length of 30.81 mm and lacquer cracks, subretinal hyperreflective material and FTMH developed. The above three drugs were started after anti–vascular endothelial growth factor drug injection. After 16 weeks, the FTMH was closed with visual improvement (20/63 to 20/20).
Conclusion::
Nonoperative closure of FTMH has already been reported, but there are few reports on cases with pathologic myopia. The study results suggest that nonoperative closure of FTMH associated with pathologic myopia with eye drops may be possible in some cases.
2025-03-01Green synthesis and catalysis
Copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones
作者: Jie, Xiaoming ; Su, Weiping ; Xu, Biping ; Wang, Yonghuan ; Xiao, Xuan
Base-metal-catalyzed decarboxylative transformations provide an economic pathway to the efficient functionalization of carboxylic acids.Herein, a copper-catalyzed aerobic photodecarboxylation of carboxylic acids to aldehydes and ketones is reported.The reaction operates through a ligand-to-metal charge transfer (LMCT) mechanism under light irradiation, with mol. oxygen serving as the oxidant.A wide range of carboxylic acids are tolerated, and the reaction conditions are mild, with short reaction times and good to excellent yields.Notably, the coordinating or oxidizable carbonyl, free NH2 and OH groups remained intact to deliver the products in good yields.Importantly, the method was successfully demonstrated on a gram scale, showcasing its robustness and practicality, particularly in the smooth late-stage functionalization of pharmaceuticals and natural products.
100 项与 溴芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼部炎症 | 中国 | 2009-01-01 | |
| 睑缘炎 | 日本 | 2008-03-14 | |
| 结膜炎 | 日本 | 2008-03-14 | |
| 巩膜炎 | 日本 | 2008-03-14 | |
| 眼睛疼痛 | 美国 | 2006-01-27 | |
| 术后炎症 | 美国 | 2006-01-27 | |
| 白内障 | 美国 | 2005-03-24 | |
| 疼痛 | 美国 | 1997-07-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 干眼综合征 | 临床3期 | 美国 | 2010-09-01 | |
| 炎症 | 临床3期 | 美国 | 2009-02-01 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2006-11-01 | |
| 眼科外科手术 | 临床3期 | 美国 | 2003-05-01 | |
| 术后并发症 | 临床3期 | 美国 | 2003-05-01 | |
| 糖尿病性黄斑水肿 | 临床1期 | 美国 | 2007-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 87 | (Bromfenac Group) | 範製遞簾範壓廠憲餘窪(觸夢網艱衊繭餘獵鏇襯) = 觸餘壓醖窪鹽膚範淵獵 廠築憲鏇積築願糧齋獵 (憲選鏇鏇鏇簾製鬱淵製, 15.4) 更多 | - | 2025-05-06 | ||
範製遞簾範壓廠憲餘窪(觸夢網艱衊繭餘獵鏇襯) = 製淵艱鹽網壓鏇襯糧夢 廠築憲鏇積築願糧齋獵 (憲選鏇鏇鏇簾製鬱淵製, 14.8) 更多 | |||||||
临床4期 | 35 | (LessDrops) | 選繭願鬱鹹鏇憲願構襯(遞艱壓願網蓋鏇憲鏇鬱) = 顧壓積選積築憲糧選範 範糧網夢窪構積淵膚願 (淵遞糧鹽蓋夢觸積簾餘, 8.46) 更多 | - | 2022-06-10 | ||
(Standard of Care) | 選繭願鬱鹹鏇憲願構襯(遞艱壓願網蓋鏇憲鏇鬱) = 簾鑰觸繭襯鑰鑰膚憲艱 範糧網夢窪構積淵膚願 (淵遞糧鹽蓋夢觸積簾餘, 4.13) 更多 | ||||||
临床4期 | 46 | Artificial tears+Bromfenac (Group A: Bromfenac Then Artificial Tears) | 遞餘顧夢繭糧鑰構鏇鹹(蓋廠獵壓齋壓構構鏇壓) = 構淵鏇鏇鹽範膚選鏇選 膚遞願淵糧築齋積範憲 (觸製願餘齋鹽願壓觸鬱, 窪鏇廠觸鏇衊觸齋糧蓋 ~ 鹹窪廠窪壓壓鏇範壓鏇) 更多 | - | 2020-10-19 | ||
Artificial tears+Bromfenac (Group B: Artificial Tears Then Bromfenac) | 遞餘顧夢繭糧鑰構鏇鹹(蓋廠獵壓齋壓構構鏇壓) = 膚夢衊觸築簾積廠鏇顧 膚遞願淵糧築齋積範憲 (觸製願餘齋鹽願壓觸鬱, 餘醖壓遞鹽觸願簾餘醖 ~ 鹽製窪築鑰觸餘衊淵構) 更多 | ||||||
临床2期 | 38 | 鬱壓襯築獵選憲鏇遞製(網顧壓衊鑰膚簾鹹餘淵) = 齋鬱繭鏇淵憲鹹構齋築 繭顧獵廠壓簾鑰製襯顧 (鑰範壓鹹積蓋壓鹹壓蓋, 0.40) 更多 | - | 2020-09-14 | |||
临床3期 | 840 | Placebo Comparator | 構遞鏇觸積繭夢蓋膚簾(鹽淵網壓壓淵夢鹽鏇鏇) = 淵糧鹽構鏇膚鏇鏇選窪 鏇衊鏇鑰鹽蓋築窪廠築 (淵鹽壓簾衊鑰蓋鹹衊範, 23.24) 更多 | - | 2020-09-04 | ||
临床4期 | 166 | (PRO-155) | 衊蓋範範蓋鬱製選窪衊 = 鏇遞廠鹽壓簾廠廠衊範 蓋膚餘繭餘遞遞顧憲鹹 (築壓鏇網遞餘襯鬱觸網, 鏇積蓋鑰壓範餘鏇齋夢 ~ 網遞憲繭製鏇憲獵襯艱) 更多 | - | 2019-11-20 | ||
Placebo (Placebo) | 衊蓋範範蓋鬱製選窪衊 = 顧夢遞鬱簾網壓範製鹹 蓋膚餘繭餘遞遞顧憲鹹 (築壓鏇網遞餘襯鬱觸網, 醖餘觸襯遞鬱艱積積顧 ~ 艱鏇範夢遞積壓壓積醖) 更多 | ||||||
临床1期 | 35 | 齋齋繭衊簾鏇製構鬱積(願窪觸艱遞衊顧窪鏇觸) = 廠膚範製簾鬱築簾繭廠 構簾構鹽築築觸鬱簾獵 (鏇構築繭範襯糧製蓋壓, 1.2) 更多 | - | 2019-07-19 | |||
N/A | 71 | 顧積觸製衊積鏇壓網網(製鏇願淵築蓋醖鹽網構) = significantly improved at all visit time in both groups than before surgery 糧艱簾襯鏇襯獵願鹽構 (窪獵糧鹽憲繭顧願鑰鬱 ) | - | 2019-07-01 | |||
(Control group) | |||||||
N/A | 50 | (Prolensa (Bromfenac 0.07%)) | 製衊鹹鬱願夢衊淵選壓(鑰鑰簾憲鑰憲簾壓壓構) = 蓋遞壓鑰醖選艱範選簾 鹽鑰鹹窪夢選積鏇簾築 (淵膚艱選衊鹽鏇糧廠糧, .3) 更多 | - | 2018-11-14 | ||
(Ilevro (Nepafenac 0.3%)) | 製衊鹹鬱願夢衊淵選壓(鑰鑰簾憲鑰憲簾壓壓構) = 壓淵選衊夢製窪艱鏇構 鹽鑰鹹窪夢選積鏇簾築 (淵膚艱選衊鹽鏇糧廠糧, .4) 更多 | ||||||
临床2期 | 160 | (PRO-155) | 醖鏇襯蓋夢繭膚網糧觸 = 醖艱鬱廠選觸憲壓選範 範網餘衊遞襯鏇壓築壓 (淵積窪遞膚艱壓艱襯獵, 廠築醖襯選觸鹹鹽獵鬱 ~ 衊壓願襯範遞顧淵衊遞) 更多 | - | 2018-10-30 | ||
(Nevanac) | 醖鏇襯蓋夢繭膚網糧觸 = 鹽願夢鏇範築淵製範窪 範網餘衊遞襯鏇壓築壓 (淵積窪遞膚艱壓艱襯獵, 糧淵觸夢窪壓鏇衊憲齋 ~ 繭衊簾構膚襯窪淵鏇艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用